Tharimmune, Inc. | Finanzwire

Basculer en Français

8298	Companies
114933	Keywords
55342	Articles
62466	Press releases

Home
Companies
Tharimmune, Inc.

BRIEF

published on 04/30/2024 at 14:36, 6 months 20 days ago

Tharimmune to Engage Investors at Two Major Conferences in May

Biotechnology Investor Conferences Investor Engagement Tharimmune Inflammation And Immunology
PRESS RELEASE

published on 04/30/2024 at 14:31, 6 months 20 days ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May
Tharimmune to present at investor conferences in May 2024, showcasing developments in inflammation & immunology therapies. CEO to participate in Planet MicroCap Showcase: VEGAS 2024 & EF Hutton Annual Global Conference

Investor Conferences Tharimmune Inflammation Immunology Therapeutic Candidates
BRIEF

published on 04/23/2024 at 13:36, 6 months 28 days ago

Tharimmune Secures Rights to Develop Innovative Antibody Drug Conjugates

Tharimmune, Inc. HER2/HER3 Antibodies Antibody Drug Conjugates (ADCs) Cancer Immunology Novel Therapeutics
PRESS RELEASE

published on 04/23/2024 at 13:31, 6 months 28 days ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Tharimmune, Inc. obtains rights from Washington University to develop human HER2 antibodies, expanding its pipeline of novel tunable antibodies for HER2 & HER3

Biotechnology Tharimmune Inc. Washington University HER2 Antibodies Novel Antibodies
PRESS RELEASE

published on 02/20/2024 at 14:01, 9 months 1 day ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Tharimmune, Inc. announces successful Phase 1 trial completion for TH104, a promising treatment for chronic pruritus in primary biliary cholangitis. The study shows positive safety and tolerability profile aligned with previous findings

Tharimmune Inc. TH104 Phase 1 Trial Chronic Pruritus Primary Biliary Cholangitis
BRIEF

published on 02/20/2024 at 14:01, 9 months 1 day ago

Tharimmune announces positive Phase 1 results for TH104 and funding until 2025

Biotechnology Phase 1 Clinical Trial Funding TH104 Primary Biliary Cholangitis
PRESS RELEASE

published on 02/05/2024 at 14:30, 9 months 15 days ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. completes first patient dosing in Phase 1 clinical trial for TH104, an oral thin film targeting liver-related and pruritogenic inflammatory conditions. Topline data expected in 2Q24 with full readout shortly after. Company fully funded into 2025 for Phase 1 and 2 readouts

Phase 1 Clinical Trial Tharimmune Inc. TH104 Liver-related Conditions Pruritogenic Inflammatory Conditions
PRESS RELEASE

published on 01/29/2024 at 14:00, 9 months 23 days ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Tharimmune, Inc. initiates Phase 1 trial for TH104, a buccal film with nalmefene for liver-related pruritogenic inflammatory conditions. Phase 2 planning for PBC, near-clinical pipeline and R&D day planned. Company fully funded into 2025

Tharimmune Inc. TH104 Phase 1 Trial Buccal Film Chronic Pruritus
PRESS RELEASE

published on 12/11/2023 at 14:01, 11 months 10 days ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
PRESS RELEASE

published on 11/27/2023 at 14:00, 11 months 24 days ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Accesswire

Published on 11/21/2024 at 14:00, 12 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 12 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 12 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 12 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report
Published on 11/21/2024 at 13:30, 42 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:00, 12 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 57 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 37 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 57 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 2 hours 6 minutes ago

IVU AG publishes Quarterly Report Q3-2024

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 14 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 52 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 27 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 27 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE